FENC
Income statement / Annual
Last year (2024), Fennec Pharmaceuticals Inc.'s total revenue was $47.54 M,
an increase of 123.69% from the previous year.
In 2024, Fennec Pharmaceuticals Inc.'s net income was -$436.00 K.
See Fennec Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$47.54 M |
$21.25 M |
$1.47 M |
$0.00 |
$170.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.18 M
|
$1.26 M
|
$82.59 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$44.35 M
|
$19.99 M
|
$1.39 M
|
$0.00
|
$170.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.93
|
0.94
|
0.94
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$307.00 K
|
$56.00 K
|
$3.39 M
|
$4.94 M
|
$5.11 M
|
$5.74 M
|
$5.01 M
|
$1.94 M
|
$472.00 K
|
$256.00 K
|
| General & Administrative Expenses |
$23.05 M
|
$20.59 M
|
$0.00
|
$0.00
|
$12.95 M
|
$0.00
|
$5.40 M
|
$5.02 M
|
$2.40 M
|
$1.63 M
|
| Selling & Marketing Expenses |
$18.43 M
|
$12.12 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.48 M
|
$32.71 M
|
$19.69 M
|
$12.13 M
|
$12.95 M
|
$7.57 M
|
$5.40 M
|
$5.02 M
|
$2.40 M
|
$1.63 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.00 K
|
-$8.00 K
|
-$14.00 K
|
$0.00
|
| Operating Expenses |
$41.79 M
|
$32.76 M
|
$23.09 M
|
$17.07 M
|
$18.06 M
|
$13.31 M
|
$10.41 M
|
$6.95 M
|
$2.87 M
|
$1.89 M
|
| Cost And Expenses |
$44.97 M
|
$34.02 M
|
$23.17 M
|
$17.07 M
|
$18.06 M
|
$13.31 M
|
$10.41 M
|
$6.95 M
|
$2.87 M
|
$1.89 M
|
| Interest Income |
$1.59 M
|
$441.00 K
|
$195.00 K
|
$54.00 K
|
$91.60 K
|
$322.32 K
|
$0.00
|
$0.00
|
$0.00
|
$3.00 K
|
| Interest Expense |
$4.07 M
|
$3.39 M
|
$978.00 K
|
$126.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$800.00 K
|
$287.00 K
|
$0.00
|
$0.00
|
$17.89 M
|
$0.00
|
$10.41 M
|
$6.95 M
|
$2.87 M
|
-$1.23 M
|
| EBITDA |
$4.80 M |
-$12.36 M |
-$21.69 M |
-$17.07 M |
$0.00 |
-$13.07 M |
$521.00 K |
-$95.00 K |
$82.00 K |
-$1.89 M |
| EBITDA Ratio |
0.1
|
-0.58
|
-14.71
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0.05
|
-0.6
|
-14.72
|
0
|
-105.21
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.64 M
|
-$3.27 M
|
-$1.08 M
|
-$121.92 K
|
-$224.00 K
|
$239.44 K
|
$521.00 K
|
-$95.00 K
|
$82.00 K
|
$1.28 M
|
| Income Before Tax |
-$71.00 K
|
-$16.05 M
|
-$22.77 M
|
-$17.19 M
|
-$18.11 M
|
-$13.07 M
|
-$9.89 M
|
-$7.05 M
|
-$2.79 M
|
-$659.00 K
|
| Income Before Tax Ratio |
-0
|
-0.75
|
-15.45
|
0
|
-106.52
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$365.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$348.00 K
|
-$47.00 K
|
-$8.00 K
|
-$3.00 K
|
| Net Income |
-$436.00 K
|
-$16.05 M
|
-$22.77 M
|
-$17.19 M
|
-$18.11 M
|
-$13.07 M
|
-$9.89 M
|
-$7.05 M
|
-$2.79 M
|
-$659.00 K
|
| Net Income Ratio |
-0.01
|
-0.75
|
-15.45
|
0
|
-106.52
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.016 |
-0.6 |
-0.95 |
-0.67 |
-0.76 |
-0.63 |
-0.52 |
-0.47 |
-0.22 |
-0.0609 |
| EPS Diluted |
-0.016 |
-0.6 |
-0.95 |
-0.67 |
-0.76 |
-0.63 |
-0.52 |
-0.47 |
-0.22 |
-0.0609 |
| Weighted Average Shares Out |
$27.29 M
|
$26.57 M
|
$26.28 M
|
$26.01 M
|
$23.70 M
|
$19.90 M
|
$18.94 M
|
$14.99 M
|
$12.68 M
|
$10.83 M
|
| Weighted Average Shares Out Diluted |
$27.29 M
|
$26.57 M
|
$26.28 M
|
$26.01 M
|
$23.70 M
|
$19.90 M
|
$19.02 M
|
$15.01 M
|
$12.77 M
|
$10.83 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
